Biogen Turns To Plegridy As Avonex Sales Wane
This article was originally published in The Pink Sheet Daily
Executive Summary
The MS powerhouse got approval for its fourth treatment for the disease; the drug will help bolster the franchise while sales of some of the other drugs are eroded.
You may also be interested in...
Biogen Leans On Plegridy To Help Extend The Life Of Avonex
The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.
Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients
Given the risks of progressive multifocal leukoencephalopathy, a proposed restriction appears aimed at blunting the potentially unfavorable impact that longer duration of use in the first-line setting would have on natalizumab’s risk/benefit profile.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.